After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...
A new study has confirmed that weight loss or bariatric surgery is safe and very effective, and, for a large percentage of ...
Anne-Marie Zanzal, 60, and her wife Tonda McKay, 62, have also experienced the more positive changes that weight-loss drugs ...
Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results